OncoGenex Pharmaceuticals Inc.'s President and CEO just picked up 19,159 shares

Scott Daniel Cormack, OncoGenex Pharmaceuticals Inc.'s President and CEO and a director of the company, recently acquired 19,159 shares of the company. The buys took place at prices ranging from $0.00 to $3.17 per share, on dates ranging from August 12 to August 13, 2014. Cormack now owns 84,139 shares of the company. Cormack operates out of Vancouver, A1. Some additional info was provided as follows:

Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II. Represents shares of common stock that have been sold by the issuer to satisfy the tax liability in connection with the settlement of RSUs. Each RSU represents a contingent right to receive one share of the issuer's common stock at settlement. Pursuant t o the terms of the RSU, the total underlying shares vest when certain performance criteria relating to the issuer are met. The RSUs expire 30 days from the date they vest.

The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.

To receive a free e-mail notification whenever OncoGenex Pharmaceuticals Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Great Point Partners just provided an update on its share ownership of OncoGenex Pharmaceuticals Inc. - Feb. 17, 2015
OncoGenex Pharmaceuticals: Entry Into A Material Definitive Agreement - Feb. 12, 2015

   Auto Refresh